Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol Xinafoate
Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol Xinafoate
This study may last up to 36-38 weeks. Patients will visit the clinic 11 times. A blood
 sample will be taken at Visit 1 to look at subjects' genes. Breathing tests will be done
 during the study. Study medicines and procedures will be provided at no cost. Patients will
 be treated with VENTOLIN (8 wks), ATROVENT (8 wks), then ADVAIR or SEREVENT (16 wks). ADVAIR
 and SEREVENT are FDA approved for the treatment of asthma in patients 4 years of age and
 older.
A Randomized, Parallel Group, Double-Blind, Comparative Trial Assessing Lung Function and
 Other Measures of Asthma Control in Adults and Adolescents, at least 12 Years of Age, with
 Persistent Asthma, Who Have Either a B16-Arg/Arg, a B16-Gly/Gly or a B-16 Arg/Gly Genotype
 and are Treated With Fluticasone Propionate/Salmeterol DISKUS™ Combination Product 100/50mcg
 or Salmeterol DISKUS 50 mcg BID
Inclusion criteria:

 -  Diagnosis of persistent asthma for 3 months.

 -  Use of short-acting beta-agonist medication like VENTOLIN.

 Exclusion criteria:

 -  Hospitalization for asthma 6 months before study.

 -  Other serious diseases like congestive heart failure, uncontrolled hypertension, TB.

 -  Current use of inhaled or oral corticosteroids.